A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

Vemurafenib, a selective inhibitor of oncogenic BRAF kinase carrying the V600 mutation, is approved for treatment of advanced BRAF mutation–positive melanoma. This study characterized mass balance, metabolism, rates/routes of elimination, and disposition of (14)C-labeled vemurafenib in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldinger, Simone M, Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C, Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K, Bazan, Selby Patricia Gil, Grippo, Joseph F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324687/
https://www.ncbi.nlm.nih.gov/pubmed/25729580
http://dx.doi.org/10.1002/prp2.113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324687/
https://www.ncbi.nlm.nih.gov/pubmed/25729580
http://dx.doi.org/10.1002/prp2.113

Ejemplares similares